¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"collisionless plasma model"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • animal model
    µ¿¹°¸ðÇü
  • atomic model
    ¿øÀÚ¸ðÇü
  • additive model
    µ¡¼À¸ðµ¨
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartment model
    ±¸È¹¸ðµ¨
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±Çü¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
  • homeostatic model
    Ç׻󼺸ðÇü
  • in-the-ear model
    ±Ó¼Óº¸Ã»±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • additive model
    µ¡¼À¸ðµ¨
  • animal model
    µ¿¹°¸ðÇü
  • atomic model
    ¿øÀÚ¸ðÇü
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartment model
    ±¸È¹¸ðµ¨
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±»ó¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
  • homeostatic model
    Ç׻󼺸ðÇü
  • in-the-ear model
    ±Í¼ÓÇüº¸Ã»±â
  • linear quadratic model
    ¼±Çü¹æÇü¸ðµ¨, ¼±ÇüÀÌÂ÷ÇÔ¼ö¸ðµ¨
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾(û¡òõá¬øàÍéâÐðþ)
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼º Æó·Å.
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼ºÆó·Å(û¡òõá¬øààõøËæú)
  • plasma cell tumor
    ÇüÁú¼¼Æ÷Á¾¾ç
  • plasma cell vulvitis
    ÇüÁú¼¼Æ÷ ¿©¼ºÀ½ºÎ¿°
  • plasma clot
    Ç÷À屫.
  • plasma clot
    Ç÷À屫(úìíìÎÔ)
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma concentration
    Ç÷Àå³óµµ.
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè(úìíìÎßó©ãËúÐ).
  • plasma exchange
    Ç÷À屳ȯ
  • plasma exchange
    Çö󽺸¶±³È¯(¡­Îßüµ)
  • plasma exchange = plasmapheresis
    Ç÷À屳ȯ, Ç÷À强ºÐäÁý¼ú
  • plasma expander =p. volume e.
    ´ë¿ëÇöóÁ<Ç÷Àå>, ÇöóÁ<Ç÷Àå(úìíì )>Áõ·®Á¦(¡­ñòåÖð¥).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sequential model
    ¼øÂ÷¸ðµ¨.
  • single major gene(locus) model
    ´ÜÀÏ ÁÖ¿äÀ¯ÀüÀÚ(À¯ÀüÁÂÀ§) ¸ðµ¨
  • single target multi-hit model
    ´ÜÀÏÇ¥Àû´Ù¹ßÀûÁß ¸ðµ¨
  • social service model
    »çȸ¼­ºñ½º¸ðµ¨
  • stress and coping model
    ½ºÆ®·¹½º¿Í ´ëó(Óßô¥)¸ðµ¨.
  • symmetry model
    ´ëĪÇü(Óßöàúþ), ´ëμ³(Óß öàæò).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • viscoelastic model
    Á¡Åº¼º¸ðÇü.
  • wave model
    ÆÄÇü
  • wax model
    ³³(¿ø)Çü(ÕÅê«úþ).
  • working model
    ÀÛ¾÷¸ðÇü(ËöËâËÎÌ´).
  • working model for bridgework
    ±³ÀÇÄ¡¿ë ÀÛ¾÷¸ðÇü(ÎéëùöÍéÄíÂåöÙ¼úþ).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (¡­úìíì).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (?Ì´Ëö).
  • blood plasma
    Ç÷Àå
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Campbell model
    Ä·º§ ¸ðµ¨
  • cloverleaf model
    Ŭ·Î¹öÀÙ ¸ðµ¨
  • concerted model
    Çùµ¿(úðÔÒ) ¸ðµ¨
  • CPK model
    CPK ¸ðµ¨
  • crystallographic model
    °áÁ¤(Ì¿ïÜ) ¸ðµ¨
  • Danielli-Davson model
    ´Ù´Ï¿¤¸®-´ëºê¼Õ ¸ðµ¨
  • Danielli-Davson-Robertson model
    "= unit membrane hypothesis, ´Ù´Ï¿¤¸®-´ëºê¼Õ-·Î¹öÆ®¼Õ ¸ðµ¨"
  • distorted bond model
    ¿Ö°î°áÇÕ(èàÍØÌ¿ùê) ¸ðµ¨
  • doughnut model
    µµ¿ì³Ó ¸ðµ¨
  • Dreiding model
    µå¶óÀ̵ù ¸ðµ¨
  • erosion model
    ¹Ì¶õ(Ú¼Õ´) ¸ðµ¨
  • Ferdinand model
    Æä¸£µð³­µå ¸ðµ¨
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • fluid mosaic model
    À¯µ¿(×µÔÑ) ¸ðÀÚ
  • framework model
    °ñ°Ý(ÍéÌ«) ¸ðµ¨
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MIC maternal and infant care; medical intensive care; Medical Interfraternity Conference; microscopy; mi...
OSI open systems interconnection [reference model]
PBPK physiologically based pharmacokinetic [model]
PDM point distribution model
PRECEDE predisposing, reinforcing, and enabling causes in educational diagnosis and evaluation [model]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
POHEM POpulation HEalth Model
TTM The Transtheoretical Model
UKM Urea kinetic model
MAIDS model of AIDS
PRP 1--Platelet-rich plasma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plasma formation
    Çö󽺸¶ Çü¼º
  • plasma hemoglobin
    Ç÷Àå Çì¸ð±Û·Îºó, Ç÷Àå Ç÷¾×¼Ò
  • plasma membrane
    ¿øÇüÁú ¸·, ¼¼Æ÷ ÇüÁú¸·
    ¿øÇüÁú Ç¥¸éÀ» µ¤´Â ¿¯Àº ¸·. µÎ²²´Â 5¡­25 ¥ìmÀÌ´Ù. ±¤ÇÐÇö¹Ì°æÀ¸·Î´Â °üÂûÇÒ ¼ö ¾øÁö¸¸ ÀüÀÚÇö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÏ´Ù. ÀÌ ¸·Àº ¿øÇüÁú Ç¥¸é, Áï ¸Å¾×°úÀÇ °è¸é¿¡ Çü¼ºµÈ ÈíÂø¸· ¶Ç´Â ħÀü¸·À¸·Î »ý°¢µÈ´Ù. ¿øÇüÁú ¸·ÀÇ ºÐÀÚ ±¸Á¶´Â ·¹½ÃƾÀ̳ª ÄÝ·¹½ºÅ×·Ñ µîÀÇ Ç¥¸é Ȱ¼º ¹°Áú ºÐÀÚ°¡ 2ºÐÀÚ ÃþÀ¸·Î ±× Ç¥¸é¿¡ ¹è¿­µÇ¸ç, À̰ÍÀ» °¢ 1ºÐÀÚ ÃþÀÇ ´Ü¹éÁú ºÐÀÚ°¡ ¾çÂÊ¿¡¼­ »÷µåÀ§Ä¡ÇÑ ´ÜÀ§¸· ±¸Á¶ÀÌ´Ù. ÀüÀÚÇö¹Ì°æÀûÀ¸·Î ÀÌ ´ÜÀ§´Â ¾Ï, ¸í, ¾ÏÀÇ 3Ãþ
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma substitute
    Ç÷Àå ´ë¿ëÁ¦
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pooled plasma
    È¥ÁÖ Ç÷Àå
  • renal plasma flow
    ½Å Ç÷Àå·ù, ½Å Ç÷Àå·ù·®
  • venous plasma blood glucose
    Á¤¸Æ Ç÷Àå Ç÷´çÄ¡, Á¤¸Æ Ç÷Àå Ç÷´ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
deterministic model <epidemiology> A mathematical model in which the parameters and variables are not subject to random fluctuations, so that the system is at any time entirely defined by the initial conditions chosen. Contrast with a stochastic model.
(05 Dec 1998)
discrete time model <epidemiology> A model in which the system jumps from one state to the next at fixed intervals or timesteps. These difference models are simple to understand but often difficult to analyse; Contrast continuous time models.
The parameters in such a model refer to the amount of change over the finite timestep; they are sometimes referred to as finite rates.
In a (rather precise) sense, a differential equation is what you eventually get from a difference equation when you let the timestep get smaller and smaller and smaller.
(05 Dec 1998)
induced fit model A model to suggest a mode of action of enzymes in which the substrate binds to the active site of the protein, causing a conformational change in the protein.
Synonym: Koshland-Nemethy-Filmer model.
(05 Mar 2000)
transition probability model A model to account for the apparently random variation in cell cycle time between individual animal tissue cells in culture that postulates that transition from G1 to s phase is probabilistic. Contrasts with hypotheses that require the accumulation of critical levels of particular proteins.
(18 Nov 1997)
KNF model <abbreviation> Koshland-Nemethy-Filmer model.
(05 Mar 2000)
Koshland-Nemethy-Filmer model <biochemistry, chemistry> A model to explain the allosteric form of cooperativity; in this model, in the absence of ligands, the protein exists in only one conformation; upon binding, the ligand induces a conformational change that may be transmitted to other subunits.
Synonym: Adair-Koshland-Nemethy-Filmer model, induced fit model.
(05 Mar 2000)
fluid bilayer model Generally accepted model for membranes in cells. In its original form, the model held that proteins floated in a sea of phospholipids arranged as a bilayer with a central hydrophobic domain. Although it is now recognised that some proteins are restrained by interactions with cytoskeletal elements and that the phospholipid annulus around a protein may contain only specific types of lipid, the model is still considered broadly correct.
(18 Nov 1997)
fluid mosaic model A model used to conceptualise cell membranes, in it, the membranesare described as a structually and functionally asymmetric lipidbilayer studded with embedded proteins that aid in cross-membrane transport.
(09 Oct 1997)
lock-and-key model A model used to suggest the mode of operation of an enzyme in which the substrate fits into the active site of the protein like a key into a lock.
(05 Mar 2000)
logistic model A statistical model; in epidemiology, a model of risk as a function of exposure to a risk factor.
(05 Mar 2000)
antihemophilic plasma Human plasma in which the labile antihemophilic globulin component, present in fresh plasma, has been preserved; it is used to temporarily relieve dysfunction of the haemostatic mechanism in haemophilia.
(05 Mar 2000)
apical plasma membrane <cell biology> The term used for the cell membrane on the apical (inner or upper) surface of transporting epithelial cells.
This region of the cell membrane is separated, in vertebrates, from the baso lateral membrane by a ring of tight junctions that prevents free mixing of membrane proteins from these two domains.
(18 Nov 1997)
basolateral plasma membrane <cell biology> The plasma membrane of epithelial cells that is adjacent to the basal lamina or the adjoining cells of the sheet. Differs both in protein and phospholipid composition from the apical plasma membrane from which it is isolated by tight junctions (zonula occludentes).
(18 Nov 1997)
beam-plasma reaction <radiobiology> Fusion reaction which occurs from the collision of a fast beam ion with a thermal plasma ion.
(09 Oct 1997)
bean-shaped plasma <radiobiology> A toroidal plasma indented on the inboard side (the side with the donut hole), that results in additional stability to ballooning modes. Moderate indentation may provide access to the second-stability region (high beta).
(13 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á